Erythropoietin alfa is widely used to treat anemia and increase the red blood cells count in the body. Erythropoietin drugs are developed in vitro by extracting the erythropoietin from the human body and developing it through the use of recombinant DNA technology. Erythropoietin drugs are also used to treat anemia induced from cancer, multiple myloma and HIV associated anemia. Recombinant DNA technology has allowed researchers to develop synthetic forms of erythropoietin such as epoetin alfa, epoetin beta, epoetin delta and epoetin omega. The erythropoietin drugs market has witnessed strong adoption in the cancer and HIV associated anemia treatment. The erythropoietin alfa biosimilars have gained significant traction in the past two years and the market will witness the introduction of new biosimilars as the existing erythropoietin drugs undergo patent expiration.
Growing prevalence of Anemia and introduction of Biosimilar will drive market growth
As per the WHO report published in 2011, an estimated 800 million people are affected by Anemia globally with large prevalence observed in Asia Pacific and African region. In U.S., the prevalence rate for Anemia is 5.6% which is estimated to increase in the near future as the rate of cancer witnesses a growing trend. According to the study conducted by India Spend, India has the highest prevalence of Anemia worldwide with 10.6% of YLD’s caused due to disability. Factors such as poor sanitation facilities, lack of healthy diet and poverty are responsible for high prevalence of Anemia in the country.
The erythropoietin drugs market has seen a dramatic shift from reference drugs to biosimilar with major pharmaceutical companies such as Amgen, Novartis and Pfizer developing erythropoietin biosimilar. The growth is accounted to the fact that biosimilar are relatively easier to develop and less cost intensive which has increased the adoption rate.
Europe leads the market and Asia Pacific will witness significant growth
Europe is the largest market for erythropoietin drugs market with large patient pool, developed healthcare infrastructure and better reimbursement scenario. The pharmaceutical companies continue to introduce biosimilar in the region to compete against the reference drugs. The drug approval process is less stringent as compared to North America which leads to fast approval of drugs. The mortality rate is 1.2 per 100,000 population for Anemia across Europe. North America is going to be an important market for the erythropoietin drugs industry as the drugs under clinical trials get approval from FDA and key drugs such as Epogen and Aranesp face patent expiration
Asia Pacific region is fastest growing erythropoietin drugs market, with countries such as India and China showing lucrative growth. India has the highest prevalence of anemia in the world followed by China. According to study conducted by Stanford University, an estimated180 million people suffer from Anemia in central and eastern China with the old age population more prone to it. The market of erythropoietin drugs will grow significantly as major pharmaceutical companies continue to expand the drug manufacturing process in countries such as India, China and Japan. Factors such as less stringent regulatory scenario and commercialization of erythropoietin biosimilars in the region will drive the market forward.
Introduction of new erythropoietin biosimilar will intensify the market competition
The key players in the erythropoietin drugs market are Amgen, GlaxoSmithKline, Pfizer, Johnson & Johnson, Novartis, Biocon, Ranbaxy Laboratories and Teva Pharmaceutical ltd. Due to the high cost associated with the development of innovator drugs and the patent expiration of the first erythropoietin drug launched by Amgen, the major players in the market are introducing erythropoietin biosimilar in the market with major focus on darbepoietin alfa drug. Key biosimilar such as NuPIAO, KRN321, ErepoXen and JR-131 are present at various stages of clinical development. The market is consolidated in nature and the key pharmaceutical companies will aim to introduce erythropoietin drugs in under-penetrated markets such as India, China, Japan and U.S. to stay competitive in the market.
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.[email protected]sights.com
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.